Julio A. Urbina

Dr. Julio A. Urbina

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2009 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
JUJulio A. Urbina
Julio A. Urbina
This article presents an overview of the currently available drugs nifurtimox (NFX) and benznidazole (BZN) used against Trypanosoma cruzi, the aetiological agent of Chagas disease; herein we discuss their limitations along with potential alternatives with a focus on ergosterol biosynthesis inhibitors (EBI). These compounds are currently the most advanced candidates for new anti-T. cruzi agents given that they block de novo production of 24-alkyl-sterols, which are essential for parasite survival and cannot be replaced by a host's own cholesterol. Among these compounds, new triazole derivatives that inhibit the parasite's C14alpha sterol demethylase are the most promising, as they have been shown to have curative activity in murine models of acute and chronic Chagas disease and are active against NFX and BZN-resistant T. cruzi strains; among this class of compounds, posaconazole (Schering-Plough Research Institute) and ravuconazole (Eisai Company) are poised for clinical trials in Chagas disease patients in the short term. Other T. cruzi-specific EBI, with in vitro and in vivo potency, include squalene synthase, lanosterol synthase and squalene epoxidase-inhibitors as well as compounds with dual mechanisms of action (ergosterol biosynthesis inhibition and free radical generation), but they are less advanced in their development process. The main putative advantages of EBI over currently available therapies include their higher potency and selectivity in both acute and chronic infections, activity against NFX and BZN-resistant T. cruzi strains, and much better tolerability and safety profiles. Limitations may include complexity and cost of manufacture of the new compounds. As for any new drug, such compounds will require extensive clinical testing before being introduced for clinical use, and the complexity of such studies, particularly in chronic patients, will be compounded by the current limitations in the verification of true parasitological cures for T. cruzi infections.

13 November 2014 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
JUJulio A. Urbina
Julio A. Urbina

1 December 2012 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
FBFrederick Buckner
Frederick Buckner
JUJulio A. Urbina
Julio A. Urbina
► New drugs for Chagas disease are needed with improved safety and efficacy. ► Sterol 14-demethylase (CYP51) is essential for de novo sterol biosynthesis. ► Antifungal azole drugs kill Trypanosoma cruzi by inhibiting CYP51 activity. ► Posaconazole and ravuconazole are in Phase II clinical trials for Chagas disease. ► Investigational CYP51 inhibitors are being developed as alternatives.

1 November 2008 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JRJuliany Cola Fernandes Rodrigues
Juliany Cola Fernandes Rodrigues
JCJuan Luis Concepcion
Juan Luis Concepcion
CRCarlos Rodrigues
Carlos Rodrigues
ACAura Caldera
Aura Caldera
JUJulio A. Urbina
Julio A. Urbina
WSWanderley De Souza
Wanderley De Souza
ER-119884 and E5700, novel arylquinuclidine derivatives developed as cholesterol-lowering agents, were potent in vitro growth inhibitors of both proliferative stages of Leishmania amazonensis , the main causative agent of cutaneous leishmaniasis in South America, with the 50% inhibitory concentrations (IC 50 s) being in the low-nanomolar to subnanomolar range. The compounds were very potent noncompetitive inhibitors of native L. amazonensis squalene synthase (SQS), with inhibition constants also being in the nanomolar to subnanomolar range. Growth inhibition was strictly associated with the depletion of the parasite's main endogenous sterols and the concomitant accumulation of exogenous cholesterol. Using electron microscopy, we identified the intracellular structures affected by the compounds. A large number of lipid inclusions displaying different shapes and electron densities were observed after treatment with both SQS inhibitors, and these inclusions were associated with an intense disorganization of the membrane that surrounds the cell body and flagellum, as well as the endoplasmic reticulum and the Golgi complex. Cells treated with ER-119884 but not those treated with E5700 had an altered cytoskeleton organization due to an abnormal distribution of tubulin, and many were arrested at cytokinesis. A prominent contractile vacuole and a phenotype typical of programmed cell death were frequently found in drug-treated cells. The selectivity of the drugs was demonstrated with the JC-1 mitochondrial fluorescent label and by trypan blue exclusion tests with macrophages, which showed that the IC 50 s against the host cells were 4 to 5 orders of magnitude greater that those against the intracellular parasites. Taken together, our results show that ER-119884 and E5700 are unusually potent and selective inhibitors of the growth of Leishmania amazonensis , probably because of their inhibitory effects on de novo sterol biosynthesis at the level of SQS, but some of our observations indicate that ER-119884 may also interfere with other cellular processes.

1 January 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
DADaniel Adesse
Daniel Adesse
EAEduardo Meirelles Azzam
Eduardo Meirelles Azzam
MMMaria de Nazareth L. Meirelles
Maria de Nazareth L. Meirelles
JUJulio A. Urbina
Julio A. Urbina
LGLuciana Ribeiro Garzoni
Luciana Ribeiro Garzoni
We present the results of the first detailed study of the antiproliferative and ultrastructural effects of amiodarone on Trypanosoma cruzi , the causative agent of Chagas' disease. Moreover, we report the effects of this compound on the recovery of F-actin fibrils, connexin43, and contractility in T. cruzi -infected cardiac myocytes. Amiodarone is the most prescribed class III antiarrhythmic agent and is frequently used for the symptomatic treatment of Chagas' disease patients with cardiac compromise. In addition, recent studies identified its antifungal and antiprotozoal activities, which take place through Ca 2+ homeostasis disruption and ergosterol biosynthesis blockade. We tested different concentrations of amiodarone (2.5 to 10 μM) on infected primary cultures of heart muscle cells and observed a dose- and time-dependent effect on growth of the clinically relevant intracellular amastigote form of T. cruzi . Ultrastructural analyses revealed that amiodarone had a profound effect on intracellular amastigotes, including mitochondrial swelling and disorganization of reservosomes and the kinetoplast and a blockade of amastigote-trypomastigote differentiation. Amiodarone showed no toxic effects on host cells, which recovered their F-actin fibrillar organization, connexin43 distribution, and spontaneous contractility concomitant with the drug-induced eradication of the intracellular parasites. Amiodarone is, therefore, a promising compound for the development of new drugs against T. cruzi .